Simulation Plus (NASDAQ: SLP) develops drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company integrates new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into its software for physiologically based pharmacokinetic modeling and simulation. The company also provides both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit the company’s website at www.simulations-plus.com